Novita takes heart implant from design to development with new financing
This article was originally published in Clinica
Executive Summary
Biopharmaceutical and medical device developer Novita Therapeutics has secured nearly $1m in angel financing, nearly nine months after the company was established. The Lenxa, Kansas firm said the recent completion of a fundraising tranche brought the total investment it has received since its founding in November 2009 to $930,000. The company will use the proceeds to develop an implantable cardiovascular device. In conjunction with the financing, Novita said it has signed on Cirtec Medical as its manufacturing partner.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.